arotinolol has been researched along with Blood Pressure, High in 14 studies
arotinolol: structure given in first source; arotinolol is the (+-)-isomer
| Excerpt | Relevance | Reference |
|---|---|---|
| "Arotinolol hydrochloride with alpha-and beta-receptor blocking action, developed in Japan, is mainly used for the treatment of hypertension." | 9.09 | [Clinical effect of arotinolol hydrochloride and its influence on renal function in elderly patients with essential hypertension]. ( Hattori, H; Hoshino, T; Iwai, K; Kawanishi, K; Kimura, Y; Matsumoto, M; Miyauchi, E; Munehira, J; Murai, H; Takasaki, M; Tsuchiya, H; Tsukio, Y; Yamada, K, 1999) |
| "To compare the effects of an alpha, beta blocker, arotinolol, in the treatment of essential hypertension between patients with a dipper and those with a non-dipper profile by means of 24-h ambulatory blood pressure monitoring (ABPM), a multicenter single blind parallel trial was carried out in five clinical centers." | 9.09 | Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers. ( Huang, J; Liu, G; Sun, N; Wu, H; Yu, Z; Zhang, Y; Zhou, Y, 2001) |
| "The current study addresses the 24-h antihypertensive efficacy and safety of arotinolol combined with a different calcium channel blocker." | 6.79 | The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study. ( Chen, W; Fang, H; Liu, X; Xu, W, 2014) |
| "Arotinolol hydrochloride with alpha-and beta-receptor blocking action, developed in Japan, is mainly used for the treatment of hypertension." | 5.09 | [Clinical effect of arotinolol hydrochloride and its influence on renal function in elderly patients with essential hypertension]. ( Hattori, H; Hoshino, T; Iwai, K; Kawanishi, K; Kimura, Y; Matsumoto, M; Miyauchi, E; Munehira, J; Murai, H; Takasaki, M; Tsuchiya, H; Tsukio, Y; Yamada, K, 1999) |
| "To compare the effects of an alpha, beta blocker, arotinolol, in the treatment of essential hypertension between patients with a dipper and those with a non-dipper profile by means of 24-h ambulatory blood pressure monitoring (ABPM), a multicenter single blind parallel trial was carried out in five clinical centers." | 5.09 | Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers. ( Huang, J; Liu, G; Sun, N; Wu, H; Yu, Z; Zhang, Y; Zhou, Y, 2001) |
| "To evaluate the preventive effect of nitrate tolerance, 24 patients with untreated hypertension were randomized to receive either carvedilol (10 mg twice a day [carvedilol group, n=8]), arotinolol (10 mg twice a day [arotinolol group, n=8]), or placebo (placebo group, n=8)." | 5.08 | Preventive effects of carvedilol on nitrate tolerance--a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol. ( Kakihana, M; Ohtsuka, S; Sugishita, Y; Watanabe, H, 1998) |
| "The current study addresses the 24-h antihypertensive efficacy and safety of arotinolol combined with a different calcium channel blocker." | 2.79 | The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study. ( Chen, W; Fang, H; Liu, X; Xu, W, 2014) |
| "Amosulalol was approximately threefold more potent than labetalol and arotinolol in decreasing blood pressure (BP) in conscious SHR." | 1.29 | Characterization of the adrenoceptor antagonistic and antihypertensive activity of oral amosulalol, a combined alpha- and beta-adrenoceptor antagonist, in hypertensive rats. ( Honda, K; Inagaki, O; Nakagawa, C; Shibasaki, M; Sudoh, K, 1994) |
| " At dosage levels similar to arotinolol, both pindolol and labetalol were less effective in preventing cerebral lesions despite lower blood pressure." | 1.28 | Prevention of cerebral stroke by arotinolol in salt-loaded SHRSP. ( Hara, Y; Maniwa, T; Miyagishi, A; Noguchi, T, 1991) |
| "Arotinolol (S-596, ARL) is a beta-adrenoceptor blocking drug with weak alpha-adrenoceptor blocking activity, and may be classified into the fourth generation." | 1.27 | Chronic effects of arotinolol (S-596) in spontaneously hypertensive rats. ( Kawashima, K; Kishi, K; Saito, K; Sokabe, H, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (28.57) | 18.7374 |
| 1990's | 7 (50.00) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fang, H | 1 |
| Chen, W | 1 |
| Liu, X | 1 |
| Xu, W | 1 |
| Abe, M | 1 |
| Mori, K | 1 |
| Nagai, K | 1 |
| Ito, S | 1 |
| Hara, Y | 2 |
| Nakahara, H | 1 |
| Miyagishi, A | 2 |
| Nakatani, H | 1 |
| Takekoshi, N | 1 |
| Murakami, E | 1 |
| Matsui, S | 1 |
| Murakami, H | 1 |
| Emoto, J | 1 |
| Hashimoto, A | 1 |
| Harasawa, Y | 1 |
| Imaizumi, T | 1 |
| Ando, S | 1 |
| Masaki, H | 1 |
| Harada, S | 1 |
| Momohara, M | 1 |
| Takeshita, A | 1 |
| Inagaki, O | 1 |
| Sudoh, K | 1 |
| Shibasaki, M | 1 |
| Nakagawa, C | 1 |
| Honda, K | 1 |
| Sasaki, H | 1 |
| Naka, K | 1 |
| Kishi, Y | 1 |
| Ohoshi, T | 1 |
| Hagihara, T | 1 |
| Matsuo, H | 1 |
| Sowa, R | 1 |
| Matsumoto, G | 1 |
| Sanke, T | 1 |
| Nanjo, K | 1 |
| Kuwajima, I | 1 |
| Suzuki, Y | 1 |
| Otsuka, K | 1 |
| Kawamura, H | 1 |
| Kuramoto, K | 1 |
| Watanabe, H | 1 |
| Kakihana, M | 1 |
| Ohtsuka, S | 1 |
| Sugishita, Y | 1 |
| Miyauchi, E | 1 |
| Matsumoto, M | 1 |
| Kimura, Y | 1 |
| Hattori, H | 1 |
| Tsukio, Y | 1 |
| Tsuchiya, H | 1 |
| Takasaki, M | 1 |
| Munehira, J | 1 |
| Yamada, K | 1 |
| Iwai, K | 1 |
| Kawanishi, K | 1 |
| Hoshino, T | 1 |
| Murai, H | 1 |
| Wu, H | 1 |
| Zhang, Y | 2 |
| Huang, J | 1 |
| Liu, G | 1 |
| Sun, N | 1 |
| Yu, Z | 1 |
| Zhou, Y | 1 |
| Maniwa, T | 1 |
| Noguchi, T | 1 |
| Kishi, K | 1 |
| Kawashima, K | 1 |
| Sokabe, H | 1 |
| Saito, K | 1 |
| Morimoto, Y | 1 |
| Kasai, A | 1 |
| Nagano, K | 1 |
| Umino, M | 1 |
| Kakuta, Y | 1 |
| Iwata, J | 1 |
| Konishi, T | 1 |
| Hamada, M | 1 |
| Nakano, T | 1 |
4 trials available for arotinolol and Blood Pressure, High
| Article | Year |
|---|---|
The efficacy and safety of arotinolol combined with a different calcium channel blocker in the treatment of Chinese patients with essential hypertension: a one-year follow-up study.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amlodipine; Anti | 2014 |
Preventive effects of carvedilol on nitrate tolerance--a randomized, double-blind, placebo-controlled comparative study between carvedilol and arotinolol.
Topics: Adrenergic Antagonists; Adult; Aged; Blood Flow Velocity; Blood Platelets; Blood Pressure; Carbazole | 1998 |
[Clinical effect of arotinolol hydrochloride and its influence on renal function in elderly patients with essential hypertension].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Antihypertensive | 1999 |
Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian | 2001 |
10 other studies available for arotinolol and Blood Pressure, High
| Article | Year |
|---|---|
Relapse of Graves' disease in a patient with pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Antithyroid Agen | 2003 |
[Antihypertensive effect of arotinolol (S-596), a new adrenergic beta blocking agent, on experimental hypertension].
Topics: Administration, Oral; Adrenergic beta-Antagonists; Animals; Heart Rate; Hypertension; Male; Propanol | 1983 |
Studies on concurrent alpha- and beta-adrenoceptor blocking action of S-596 (arotinolol).
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Aged; Blood Pressure; Cardiac Outp | 1983 |
Influence of arotinolol hydrochloride on heart rate spectrum in hypertensive subjects.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Blood Pressure; Female; Heart Rate; Humans; Hypertensi | 1994 |
Characterization of the adrenoceptor antagonistic and antihypertensive activity of oral amosulalol, a combined alpha- and beta-adrenoceptor antagonist, in hypertensive rats.
Topics: Administration, Oral; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antihypert | 1994 |
Nicardipine may impair glucose metabolism in hypertensive diabetic patients.
Topics: Adult; Aged; Atenolol; Carteolol; Diabetes Mellitus, Type 2; Diltiazem; Enalapril; Female; Glucose; | 1994 |
Effects of alpha,beta-blocker, arotinolol chloride, on 24-h blood pressure--difference between elderly and younger hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Blood Pressure; Blood Pressure Determination; | 1993 |
Prevention of cerebral stroke by arotinolol in salt-loaded SHRSP.
Topics: Adrenergic beta-Antagonists; Animals; Blood Pressure; Brain; Cerebrovascular Disorders; Disease Susc | 1991 |
Chronic effects of arotinolol (S-596) in spontaneously hypertensive rats.
Topics: Adrenergic beta-Antagonists; Aldosterone; Animals; Blood Pressure; Body Weight; Heart Rate; Hyperten | 1985 |
[Effects of arotinolol hydrochloride on hemodynamics, catecholamine levels and metabolism in patients with essential hypertension].
Topics: Adrenergic beta-Antagonists; Aged; Catecholamines; Female; Hemodynamics; Humans; Hypertension; Male; | 1988 |